

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

ANNOUNCEMENT PROFIT WARNING OF 2010 ANNUAL RESULTS OF FOSUN PHARMA

Reference is made to the overseas regulatory announcement dated 28 January 2011 (the “**Announcement**”) and issued by Fosun International Limited (the “**Company**”) in relation to the profit warning of 2010 annual results of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”), a subsidiary of the Company and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196).

The board of the directors of the Company would like to draw the attention of its shareholders and the investment public to the following information as set out in the Announcement:

I. Estimated Results of Fosun Pharma

1. Period of estimated results: 1 January 2010 to 31 December 2010.
2. Estimated results: In accordance with the estimation by Fosun Pharma, it is expected that the net profit attributable to the parent for the year ended 31 December 2010 will range from RMB850,000,000 to RMB950,000,000, representing a decrease of 60% to 65% as compared with that of 2009. Details of the financial information will be disclosed in the 2010 annual report of Fosun Pharma.
3. The above estimated results have not been audited.

II. 2009 Annual Results of Fosun Pharma

1. Net profit attributable to the parent: RMB2,498,201,836.08
2. Earnings per share: RMB2.02 (based on the total share capital of 1,237,774,909 shares as at 31 December 2009)

III. Reasons for the Expected Profit Decrease in 2010 Annual Results of Fosun Pharma Compared to the Same Period of 2009

Due to the listing of Sinopharm Group Co. Ltd. (“**Sinopharm**”), a company invested by Fosun Pharma, on The Stock Exchange of Hong Kong Limited (Stock Code: 01099) on September 2009, the equity in Sinopharm shared by Fosun Pharma (via Sinopharm Industrial Investment Co., Ltd.) correspondingly increased, resulting in an one off effect of approximately RMB1,968,000,000 on the net profit attributable to the parent of Fosun Pharma for the year ended 2009.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 28 January 2011

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.